LOS ANGELES, June 27 /PRNewswire/ -- Vista Partners announced today that it has updated coverage and maintains an $8.30 price target on Inovio Biomedical Corporation (AMEX:INO). "Inovio has compelling pre-clinical and clinical data regarding the ability of their technology to significantly enhance the potency of DNA vaccines which was shown in recent positive human interim results from three independent clinical studies. The company's technology is further validated from license agreements with two of the world's big five vaccine companies, Merck and Wyeth, plus multiple other partnerships and collaborations," said Ross Silver, Director of Research for Vista Partners. For more information and to download the report, please visit the Vista Partners website at http://www.vistap.com/.
About Vista Partners: Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. Based in Los Angeles, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners has built a name for itself in the small cap space due to its excellent performance. In 2005, Vista Partners recommendations returned 36% and in 2006, returns exceeded 50%.
About Inovio Biomedical Corporation: Inovio Biomedical is focused on developing multiple DNA-based immunotherapies and commercializing its Selective Electrochemical Tumor Ablation (SECTA) therapy. Inovio is a leader in developing human applications of electroporation, which uses brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceutical. For DNA vaccines, Inovio's technology has shown it can significantly increase levels of gene expression and immune responses. Inovio's immunotherapy partners include Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer Center, and the U.S. Army, with four DNA-based immunotherapies in Phase I clinical studies. The SECTA therapy is for locally ablating solid tumors. Inovio's technology is protected by an extensive patent portfolio covering in vivo electroporation. More information is available at http://www.inovio.com/.
Contact:
Vista Partners LLC
Ross Silver
(415) 738-6229
http://www.vistap.com/ DATASOURCE: Vista Partners CONTACT: Ross Silver of Vista Partners LLC, +1-415-738-6229, Web site: http://www.vistap.com/ http://www.inovio.com/
|